Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05546268Phase 1Active Not Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

Role: lead

NCT07119125Phase 1Recruiting

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

Role: lead

NCT06597799Phase 1Completed

First-in-human Study of MRT-6160 in Healthy Subjects

Role: lead

All 3 trials loaded